InVitae Corp (NASDAQ:NVTA) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $15.00.
Several brokerages recently weighed in on NVTA. BidaskClub upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded InVitae Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, ValuEngine upgraded InVitae Corp from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.
InVitae Corp (NASDAQ:NVTA) opened at 9.23 on Friday. The company’s market capitalization is $390.56 million. The stock’s 50 day moving average price is $9.56 and its 200-day moving average price is $9.76. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.
InVitae Corp (NASDAQ:NVTA) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.02. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. The business had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter last year, the firm earned ($0.77) earnings per share. The firm’s quarterly revenue was up 157.0% compared to the same quarter last year. Equities analysts forecast that InVitae Corp will post ($2.42) EPS for the current year.
A number of hedge funds have recently modified their holdings of NVTA. Donald L. Hagan LLC purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $111,000. Verity Asset Management Inc. purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $116,000. Nationwide Fund Advisors boosted its stake in shares of InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after buying an additional 2,987 shares in the last quarter. American International Group Inc. boosted its stake in shares of InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $200,000.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with our FREE daily email newsletter.